Crucell presents encouraging results of its malaria vaccine program
The studies presented at the conference show that a single shot of an experimental vaccine (a recombinant Adenovirus 35 (rAd35) vector expressing circumsporozoite protein (CSP)) protects mice against infection with the mouse malaria parasite Plasmodium yoelii. Crucell has shown in earlier studies, conducted in collaboration with Harvard Medical School, that its rAd35-based vaccines are not hampered by pre-existing adenovirus 5 (Ad5) immunity. In contrast to Ad35, antibodies to Ad5 are widespread among humans of all ages and are known to lower the immune response and thereby impair rAd5-based vaccine efficacy. Despite this, the most commonly used recombinant vaccine systems are currently based on Ad5.
Internationally renowned Dr. Moriya Tsuji from NYU commented, "We have previously demonstrated the efficacy of rAd5-based malaria vaccines in mice without pre-existing Ad5 immunity. In the present studies we found that the CSP-specific immune responses as well as the protective anti-malarial immunity were as high for rAd35 as for rAd5. However, in view of the prevalent pre-existing immunity to rAd5 among humans, these results suggest the superiority of the rAd35 vector as a potentially more effective malaria vaccine vector."
Most read news
Topics
Organizations
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous